A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma

BACKGROUND: KW-2478 is a novel non-ansamycin Hsp90 inhibitor with modest single-agent activity in relapsed/refractory myeloma but which shows synergistic antimyeloma activity with bortezomib (BTZ) in preclinical studies. This study determined the safety, preliminary clinical activity, and pharmacoki...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavenagh, J, Oakervee, H, Baetiong-Caguioa, P, Davies, F, Gharibo, M, Rabin, N, Kurman, M, Novak, B, Shiraishi, N, Nakashima, D, Akinaga, S, Yong, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672925/
https://www.ncbi.nlm.nih.gov/pubmed/28873084
http://dx.doi.org/10.1038/bjc.2017.302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672925/
https://www.ncbi.nlm.nih.gov/pubmed/28873084
http://dx.doi.org/10.1038/bjc.2017.302

Ejemplares similares